CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
B Validates platform’s ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordinated immune activation Powered by… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
Copper Run Marks 18 Years as Middle-Market M&A Enters a New Era of Complexity
B Record performance reflects growing demand for creative deal structuring and experienced advisory amid shifting market dynamics COLUMBUS, Ohio, April 23, 2026 /PRNewswire/ — Middle-market… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
AP Strange SummaryBrief at 8:01 a.m. EDT
A A court orders Zambian government to return ex-president’s body to a funeral home in bizarre dispute JOHANNESBURG (AP) — A dispute over the remains… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
FLOWERS STILL REIGN SUPREME: 75% OF CONSUMERS CHOOSE BLOOMS FOR MOTHER’S DAY
B 1-800-Flowers Marks 50 Years of Celebrating Moms with New Insights on How America Is Gifting in 2026 JERICHO, N.Y., April 23, 2026 /PRNewswire/ — Flowers… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
¿Cuál es el secreto para disfrutar de la comodidad en todo el hogar? Un calentador de agua más inteligente y eficiente
B (BPT) – Imagine esto: es una noche fría y ha estado contando los minutos para disfrutar de una larga y relajante ducha con agua… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes
P MTX-101 demonstrated decreases in self-reactive pathogenic T cells, improved β cell viability, and—at higher dose levels—numeric increase of C-peptide production SEATTLE and BRISBANE, Australia, April 23,… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION
P Novel bispecific antibody with a dual mechanism of action targeting anemia of inflammation in chronic kidney disease, autoimmune disease, and cancer Experienced leadership and… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
B NEW YORK, April 23, 2026 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
ID.me Names Gary Sun Chief Marketing Officer to Drive Next Phase of Company Growth
B MCLEAN, Va., April 23, 2026 /PRNewswire/ — ID.me, the market-leading digital identity wallet, today announced that Gary Sun has joined the company as Chief Marketing… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
UNILEVER FOOD SOLUTIONS REDEFINES FOODSERVICE STRATEGY WITH FUTURE MENUS 2026
B New ‘Experiential Intelligence Model’ to Power a Forthcoming AI Recipe Tool, Replacing Static Trend Reports WAGENINGEN, Netherlands, April 23, 2026 /PRNewswire/ — Unilever Food… Login to continue reading Login Sign up for complimentary access Sign Up Now Close
